九洲药业
(603456)
| 流通市值：164.01亿 | | | 总市值：164.01亿 |
| 流通股本：8.89亿 | | | 总股本：8.89亿 |
| 报告期 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 4,160,487,725.65 | 2,870,947,333.22 | 1,490,269,186.29 | 5,160,584,725.38 |
| 营业收入 | 4,160,487,725.65 | 2,870,947,333.22 | 1,490,269,186.29 | 5,160,584,725.38 |
| 二、营业总成本 | 3,195,334,808.19 | 2,196,824,757.62 | 1,154,593,465.07 | 4,227,810,994.3 |
| 营业成本 | 2,598,161,194.94 | 1,795,778,515.38 | 932,606,998.63 | 3,417,168,674.67 |
| 税金及附加 | 56,418,015.52 | 37,231,505.06 | 20,520,982.63 | 55,954,062.32 |
| 销售费用 | 76,615,206.8 | 51,174,804.96 | 22,944,744.54 | 99,897,934.73 |
| 管理费用 | 287,210,556.75 | 192,126,851.4 | 115,291,574.36 | 417,726,997.48 |
| 研发费用 | 194,755,936.65 | 128,066,979.29 | 67,680,193.57 | 314,912,328.62 |
| 财务费用 | -17,826,102.47 | -7,553,898.47 | -4,451,028.66 | -77,849,003.52 |
| 其中:利息费用 | 5,779,648.27 | 4,195,939.83 | 2,381,863.17 | 19,377,418.23 |
| 其中:利息收入 | 33,434,990.25 | 16,960,889.3 | 6,122,453.87 | 86,063,888.8 |
| 三、其他经营收益 | | | | |
| 加:投资收益 | -2,938,045.57 | -1,839,698.01 | -982,573.49 | -8,132,266.51 |
| 资产处置收益 | -3,928,629.58 | -1,859,197.68 | -221,826.43 | -3,156,554.9 |
| 资产减值损失(新) | -90,619,499.16 | -40,716,046.36 | -27,202,298.57 | -218,481,518.23 |
| 信用减值损失(新) | 20,837,557.46 | 7,218,213.88 | -2,563,081.82 | -16,628,744.16 |
| 其他收益 | 23,846,745.27 | 16,664,750.26 | 6,703,397.46 | 45,811,806.57 |
| 四、营业利润 | 912,351,045.88 | 653,590,597.69 | 311,409,338.37 | 732,186,453.85 |
| 加:营业外收入 | 2,613,928 | 1,091,648.39 | 175,458.03 | 1,781,303.01 |
| 减:营业外支出 | 5,157,578.23 | 4,367,448.92 | 1,064,448.05 | 3,365,334.85 |
| 五、利润总额 | 909,807,395.65 | 650,314,797.16 | 310,520,348.35 | 730,602,422.01 |
| 减:所得税费用 | 161,133,051.61 | 123,700,893.45 | 60,622,057.31 | 123,534,905.18 |
| 六、净利润 | 748,674,344.04 | 526,613,903.71 | 249,898,291.04 | 607,067,516.83 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 748,674,344.04 | 526,613,903.71 | 249,898,291.04 | 607,067,516.83 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 747,652,814.09 | 525,831,348.24 | 250,202,958.78 | 606,096,350.9 |
| 少数股东损益 | 1,021,529.95 | 782,555.47 | -304,667.74 | 971,165.93 |
| 扣除非经常损益后的净利润 | 745,937,192.29 | 525,849,368.85 | 250,663,852.13 | 593,522,422.32 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.84 | 0.59 | 0.28 | 0.68 |
| (二)稀释每股收益 | 0.84 | 0.59 | 0.28 | 0.68 |
| 八、其他综合收益 | 3,761,640.59 | 7,280,131.47 | 3,364,061.56 | 6,222,572.26 |
| 归属于母公司股东的其他综合收益 | 3,761,640.59 | 7,280,131.47 | 3,364,061.56 | 6,222,572.26 |
| 九、综合收益总额 | 752,435,984.63 | 533,894,035.18 | 253,262,352.6 | 613,290,089.09 |
| 归属于母公司股东的综合收益总额 | 751,414,454.68 | 533,111,479.71 | 253,567,020.34 | 612,318,923.16 |
| 归属于少数股东的综合收益总额 | 1,021,529.95 | 782,555.47 | -304,667.74 | 971,165.93 |
| 公告日期 | 2025-10-16 | 2025-08-06 | 2025-04-15 | 2025-04-11 |
| 审计意见(境内) | | | | 标准无保留意见 |